Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Oncology Pubmed
Loading next page...
 
/lp/pubmed/lorlatinib-in-patients-with-alk-positive-non-small-cell-lung-cancer-ZwYq5KqyLJ

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.
ISSN
1470-2045
eISSN
1474-5488
DOI
10.1016/S1470-2045(18)30649-1
pmid
30413378

Abstract

Journal

The Lancet OncologyPubmed

Published: Jun 17, 2019

There are no references for this article.